Viriom Presented the Results of Efficacy Studies of its Innovative HIV Treatment at Moscow International Virology Week

Dr. Vadim Bychko, Research Director at Viriom, announced the results of efficacy studies of Viriom's innovative candidate for treatment of HIV/AIDS at the "Moscow International Virology Week" conference. Viriom's innovative drug VM-1500 demonstrated its unique pharmacokinetic characteristics in the clinical studies, exhibiting high efficiency and resistance to HIV that surpass those of other drugs in its class. 

Scientific and practical conference "International Virology Week" is a global event which brings together the leading scientists of Russia and the world to discuss critical issues related to the development of new antiviral drugs, diagnostics and prevention of various viral infections. This year's conference brought together about 100 of the best foreign experts in the field of virology from Western Europe and the United States.

One of the key themes of the conference, given the global nature of the problem, was the fight against HIV. According to WHO and UNICEF about 34 million people are living with HIV in the world today, and this number is increasing annually by about 500,000 cases of new infections*. The modern methods of treatment allow to significantly reduce mortality and increase the length and quality of life of infected patients. However, the main challenge facing scientists around the globe is to develop a drug that would completely eradicate the virus. According to the head of the Moscow Municipal Center for AIDS Prevention and Control, Alexei Mazus, Russia has its unique experience in dealing with this sensitive issue.

In 2009 Viriom signed a licensing deal on technology transfer with the Swiss company «Hoffmann-La Roche» and won the rights to develop and manufacture an innovative candidate for the treatment of HIV/AIDS in Russia and the CIS. Viriom completed preclinical studies and is currently conducting a number of Russian and international clinical trials. The findings suggest the superiority of VM-1500 over existing drugs in the same class in efficiency and ability to resist HIV virus mutations. In his report, "Safety, pharmacokinetics and efficacy of VM-1500, a new non-nucleoside reverse transcriptase inhibitor, in healthy volunteers and HIV-infected patients," Dr. Bychko stated that the results of international clinical trials conducted in the Russian Federation and Thailand show drug VM-1500 to be safe. It is well tolerated by healthy volunteers and patients with chronic HIV-1 infection with single and repeated oral administration and has favorable pharmacokinetic properties. In addition, high clinical efficacy of the drug has manifested itself in a sharp drop in titers of HIV-1 (1.73 log10), nearing the maximum theoretically possible, in all patients treated with the lowest dose of the drug (20 mg) daily for seven days. According to the results of clinical trials presented, VM-1500 can become the best drug in its class.

Andrey Ivaschenko, Chairman of the Board at ChemRar High-Tech Center commented, "For Russia, it was the first transfer deal involving Big Pharma where the development [of a drug candidate] was transferred to a Russian company for bringing it to manufacturing, so it was important for the primary clinical trials to confirm the expectations of the partners, and now there is a high probability that the best drug in the world in this class can be produced in the Russian Federation."

One of the first supporters of Viriom in the development of VM-1500 was The Ministry of Industry and Trade of the Russian Federation, as Viriom's project fell under the framework of the Federal Program "Development of the Russian Federation, the pharmaceutical and medical industry for the period until 2020 and beyond."

About Viriom

Viriom Ltd. is a member of ChemRar group of companies involved in developing innovative antiviral drugs and combinations, treatment methods, and diagnostics. Viriom conducts scientific research in Russia, tapping into the experience and knowledge of Russian scientists, and abroad within the framework of a broad international partnership. The ChemDiv Research Institute is Viriom's major partner in pre-clinical and clinical research. Clinical studies within Russia are conducted at regional centers and on campus of the Moscow City Center for Preventing and Treating AIDS. Among Viriom’s international partners are Roche, Fox Chase Cancer Center (Philadelphia, PA), The Scripps Research Institute (San Diego, CA), Moscow Physics and Technology Institute, and M.P. Chumakov Institute for Poliomyelitis and Viral Encephalitis (Moscow, Russia). The "Viriom" project was approved by the Presidential Commission on Modernization of the Russian Federation.

Moscow International Virology Week

Moscow International Virology Week was held in Moscow from 8 to 12 September with the support of the Moscow Health Department, Moscow City Center for AIDS Prevention and Control, Institute of Human Virology and the Global Virology Network. Leading experts in Virology from around the world participated in the scientific conference to discuss the latest scientific achievements and advanced practices to combat infections.

* Global HIV/AIDS Response: epidemic update and health sector progress towards Universal Access: progress Report 2011. Geneva, World Health Organization, 2011